Hematologic Oncology
The Polish Adult Leukemia Group focuses on chronic lymphocytic leukemia, with clinical research centered on treatment strategies for patients with untreated disease and the use of combination therapy in this setting.
- Chronic lymphocytic leukemia
- Leukemia treatment
- Adult hematologic malignancies
Its research activity is concentrated in Gliwice and supported by collaborating sites across Poland.
Targeted Therapy
Clinical interest includes the use of venetoclax and rituximab in chronic lymphocytic leukemia, reflecting a focus on precision-oriented treatment approaches in blood cancer care.
- Venetoclax
- Rituximab
- Combination therapy
The sponsor’s trial portfolio is built around therapies directed at improving disease control in CLL.
Minimal Residual Disease
A major therapeutic interest is minimal residual disease assessment, with research linked to treatment adaptation based on measurable disease burden in bone marrow.
- Minimal residual disease
- Bone marrow
- Flow cytometry
This area connects response assessment with treatment decisions in leukemia care.
Clinical Response Assessment
Research interest also extends to complete response and complete response with incomplete hematological recovery, using established IWCLL criteria to evaluate treatment benefit in chronic lymphocytic leukemia.
- Complete response
- CRi
- IWCLL criteria
The sponsor’s funded research emphasizes clinically meaningful remission outcomes in adult hematology.
